S&P 500 Gains and Losses Today: Apple Stock Climbs; Eli Lilly Slumps After Disappointing Trial Results

U.S. equities were mixed on Thursday, August 7, 2025, with the S&P 500 and Dow slightly down following the implementation of new tariffs, while the Nasdaq reached a record high. Key individual stock movements included Eli Lilly plummeting 14.1% due to disappointing trial results for its experimental weight-loss pill, despite strong Q2 sales, while Fortinet shares fell 22% on an uninspiring outlook and Airbnb dropped 8% on a weaker H2 margin forecast. Conversely, medical technology firms Insulet, Becton Dickinson, and Zimmer Biomet surged on strong earnings and raised guidance, while Apple climbed over 3% on news of a potential tariff exemption for its U.S. production investment.

Analysis

The U.S. equity market exhibited significant divergence on August 7, 2025, as the implementation of new tariffs weighed on the S&P 500 and Dow, which fell 0.1% and 0.5% respectively, while the tech-heavy Nasdaq advanced 0.4% to a record high. This backdrop underscores a market driven by company-specific fundamentals rather than a monolithic reaction to trade policy. The most severe declines were seen in companies that, despite beating current earnings estimates, provided uninspiring or cautious forward guidance. Fortinet (FTNT) plummeted 22% after its outlook merely met consensus, triggering multiple analyst downgrades, while Airbnb (ABNB) dropped 8% after forecasting lower margins in the second half of the year due to increased spending. Similarly, Eli Lilly (LLY) fell 14.1% a day after disappointing Phase 3 trial results for its experimental oral weight-loss drug overshadowed strong Q2 sales and profit from its existing products. In stark contrast, the medical technology sector demonstrated robust strength, with Insulet (PODD), Becton Dickinson (BDX), and Zimmer Biomet (ZBH) surging 9.5%, 8.9%, and 8% respectively, after all three not only surpassed quarterly estimates but also raised their full-year sales outlooks. Separately, Apple (AAPL) gained over 3% on a non-earnings catalyst, reacting positively to news of a potential exemption from future chip tariffs following its commitment to a $100 billion investment in U.S. production.

Key Decisions for Investors

• Given the significant divergence between winning and losing stocks, investors should prioritize company-specific catalysts and forward guidance over broad macroeconomic headlines like tariffs.
• The sharp declines in Fortinet and Airbnb despite beating current-quarter estimates signal that for high-valuation growth stocks, an in-line or cautious outlook is being heavily penalized, warranting close scrutiny of future guidance.
• The negative reaction in Eli Lilly highlights that for pharmaceutical firms, clinical pipeline developments can significantly outweigh strong current product sales, making trial data a critical factor to monitor for long-term valuation.
• The uniform strength in the medical technology sector, with firms like Insulet and Becton Dickinson raising guidance, suggests this industry may offer a pocket of fundamental strength and positive momentum in an otherwise mixed market.
• Apple's stock gain on tariff exemption news indicates that proactive measures to align with domestic policy and de-risk supply chains can serve as a significant positive catalyst, a factor to consider when evaluating companies with global manufacturing footprints.